Recombinant human plasma gelsolin (rhu-pGSN) in a patient hospitalized with critical COVID-19 pneumonia

Abstract

Life-threatening COVID-19 pneumonia follows an exaggerated immune response to SARS-CoV-2. pGSN levels fall after SARS-CoV-2 infection. Rhu-pGSN improves outcomes in models of inflammation. In an intubated patient with critical COVID-19 pneumonia and progressive hypoxemia despite standard care, improvement became evident during rhu-pGSN infusions with full recovery within a few weeks.

Keywords

• COVID-19
• Recombinant human plasma gelsolin (rhu-pGSN)
• Inflammation